ANDA Litigation Settlements

Spring 2017

Robins Kaplan GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Case Name Drug Patent No(s). Publicly Available Terms
AstraZeneca AB v. Zydus Pharms. (USA) Inc., 14-4782 (D.N.J.) Nexium® (esomeprazole magnesium) 6,369,085; 7,411,070; 8,466,175 N/A
In re: certain consolidated roflumilast cases, 15-3375 (D.N.J.) Daliresp® (roflumilast tablets) 8,536,206; 8,604,064; 8,618,142; 5,712,298 N/A
Tyco Healthcare Group LP v. Pharm. Holdings Corp., 07-1299 (D.N.J.) Restoril® (temazepam capsules) 5,030,632; 5,211,954; 5,326,758; 5,629,310 N/A
Back to Top